Prostate cancer testing: a snapshot of the attitudes and practice of Australian general practitioners
Jane Crowe A , Addie C. Wootten A B and Nicholas Howard AA Epworth Healthcare – Australian Prostate Cancer Research Centre, Level 2, 185 Hoddle Street, Richmond, Vic. 3121, Australia.
B Corresponding author. Email: addie.wootten@epworth.org.au
Australian Journal of Primary Health 21(1) 111-114 https://doi.org/10.1071/PY13078
Submitted: 5 July 2013 Accepted: 24 September 2013 Published: 1 November 2013
Abstract
The role of the General Practitioner (GP) in testing for and managing men with prostate cancer (PCa) is significant. Very few studies have explored the attitudes and practices of Australian GPs in the context of the role of PCa testing. In this study, a 46-item web-based questionnaire was used to assess self-reported PCa testing attitudes and practices of GPs. This questionnaire was circulated to divisions of general practice and Medicare locals for further distribution to their GP members across Australia. GPs from all states and territories participated, and a total of 136 GPs completed the survey. Of the responding GPs, 57% always or usually offered PCa testing to asymptomatic men ≤70 years of age and 60% of GPs always or usually included a digital rectal examination (DRE). Many (80%) of the GPs stated that the current PCa testing guidelines were not clear. PCa testing was offered opportunistically by 56% while 39% offered testing at the patient’s request. The results captured in this study represent a snapshot of GP attitudes and practices from across Australia. The results presented indicate a wide variation in the approaches to PCa testing in general practice across Australia, which in most part appear to be related to the lack of clarity of the current prostate cancer testing guidelines.
Additional keywords: cancer care/oncology, primary care, public health, screening.
References
Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O’Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD (2009) Mortality results from a randomized prostate-cancer screening trial. The New England Journal of Medicine 360, 1310–1319.| Mortality results from a randomized prostate-cancer screening trial.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD1MXjs1ejsLk%3D&md5=0555f83dd6a42e93eca4eb6d06cea4eeCAS | 19297565PubMed |
Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O’Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC (2012) Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. Journal of the National Cancer Institute 104, 125–132.
| Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.Crossref | GoogleScholarGoogle Scholar | 22228146PubMed |
Australian Institute of Health and Welfare and Australasian Association of Cancer Registries (2010) Cancer in Australia: an overview, 2010. Cancer series no. 60. Cat. no. CAN 56. Australian Institute of Health and Welfare, Canberra.
Bowen DJ, Hannon PA, Harris JR, Martin DP (2011) Prostate cancer screening and informed decision-making: provider and patient perspectives. Prostate Cancer and Prostatic Diseases 14, 155–161.
| Prostate cancer screening and informed decision-making: provider and patient perspectives.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BC3MrgsVChuw%3D%3D&md5=eced5b37423a38084c0d5645a36508b8CAS | 21243007PubMed |
Department of Health and Ageing (2013) GP workforce Statistics 1984–85 to 2011–12. Available at http://www.health.gov.au/internet/main/publishing.nsf/Content/General+Practice+Statistics-1 [Verified 9 September 2013]
Drummond FJ, Carsin A, Sharp L, Comber H (2009) Factors prompting PSA-testing of asymptomatic men in a country with no guidelines: a national survey of general practitioners. BMC Family Practice 10, 3
| Factors prompting PSA-testing of asymptomatic men in a country with no guidelines: a national survey of general practitioners.Crossref | GoogleScholarGoogle Scholar | 19138385PubMed |
Gattellari M, Ward JE (2004) Will men attribute fault to their GP for adverse effects arising from controversial screening tests? An Australian study using scenarios about PSA screening. Journal of Medical Screening 11, 165–169.
| Will men attribute fault to their GP for adverse effects arising from controversial screening tests? An Australian study using scenarios about PSA screening.Crossref | GoogleScholarGoogle Scholar | 15563771PubMed |
GLOBOCAN (2008) Section of cancer information. Available at http://globocan.iarc.fr/factsheets/cancers/prostate.asp [Verified 27 August 2012]
Hoag NA, Davidson RA, Pommerville PJ (2008) Prostate cancer screening practices and attitudes among primary care physicians in Victoria, British Columbia. British Columbia Medical Journal 50, 456–460.
Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A (2009) Screening and prostate-cancer mortality in a randomized European study. The New England Journal of Medicine 360, 1320–1328.
| Screening and prostate-cancer mortality in a randomized European study.Crossref | GoogleScholarGoogle Scholar | 19297566PubMed |
Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Paez A, Maattanen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der Kwast T, Kujala PM, Blijenberg BG, Stenman UH, Huber A, Taari K, Hakama M, Moss SM, de Koning HJ, Auvinen A (2012) Prostate-cancer mortality at 11 years of follow up. The New England Journal of Medicine 366, 981–990.
| Prostate-cancer mortality at 11 years of follow up.Crossref | GoogleScholarGoogle Scholar | 22417251PubMed |
Skolarus TA, Holmes-Rovner M, Northouse LL, Fagerlin A, Garlinghouse C, Demers RY, Rovner DR, Darwish-Yassine M, Wei JT (2011) Primary care perspective on prostate cancer screening. The Nurse Practitioner 36, 39–44.
| Primary care perspective on prostate cancer screening.Crossref | GoogleScholarGoogle Scholar | 21572298PubMed |
Tasian GE, Cooperberg MR, Cowan JE, Keyashian K, Greene KL, Daniels NA, Carroll PR, Chan JM (2012) Prostate specific antigen screening for prostate cancer: knowledge of, attitudes towards, and utilization among primary care physicians. Urologic Oncology: Seminars and Original Investigations. 30, 155–160.
| Prostate specific antigen screening for prostate cancer: knowledge of, attitudes towards, and utilization among primary care physicians.Crossref | GoogleScholarGoogle Scholar | 20800514PubMed |
Tse J, Liaw ST (2004) RACGP training registrars’ perceptions and practice of prostate cancer screening. Australian Family Physician 33, 188–190.
